8 thoughts on “D13 – Cleveland

    1. Thank you for the kind words, Mandira. A key limitation of our study is that we were unable to infer substantive information about the pharmacokinetics of our compound. We would have to use a vertebrate animal model in future to determine any information about how drug moves throughout the body.

  1. Hi Joey, great job on your presentation! In what other contexts has Aeroplysinin-1 been studied previously?

    1. Hi Zahra, thank you very much for the positive comments. Aeroplysinin-1 has been studied as an antibiotic in gram positive bacteria. It has been investigated as a potential chemotherapy and has shown efficacy at inhibiting angiogenesis in vitro and in vivo.

    1. Hi Jessica, great question. A key question in cancer treatment is to understand how novel treatments compare to the best available treatments for specific cancers. Our experiment tested if aeroplysinin-1 was synergistic with radiation therapy, i.e. did aeroplysinin-1 and radiation kill more flies together than the sum of the two separately. Our results showed that aeroplysinin-1 was not synergistic and thus not as effective as other potential compounds that are synergistic with radiation. However, given the variability in the food in the experiment, we think future work should focus on examining a variety more doses of aeroplysinin-1 to determine if it works synergistically with radiation in our model organism.

    1. Hi Joyce. Dosage concentrations were hits if the percent survival from that dose was 2 Standard deviations above or below the mean of the negative control. 2 Standard deviations above / below the mean of the negative control means that any sample that lies beyond that range has less than a 5% chance of falling within the normal distribution of the negative control, i.e. it is very likely to be a chemotherapeutic or radiation protector relative to the negative control.

Leave a Reply